Clinical significance of angiogenic factors in breast cancer

Breast Cancer Research and Treatment

Volumn 52, Issue 1-3, 1998, Pages 159-173

  Locopo, Nathalia ^a   Fanelli, Massimo ^a   Gasparini, Giampietro ^a  

^a BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

Author keywords

Angiogenesis; Angiogenic factors; Breast cancer; Prediction; Prognosis

Indexed keywords

ANGIOGENIC FACTOR; CELL ADHESION MOLECULE; GROWTH FACTOR; INTEGRIN; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; THROMBOSPONDIN; THYMIDINE PHOSPHORYLASE; VASCULOTROPIN;

ANGIOGENESIS; BREAST CANCER; CANCER GROWTH; DIAGNOSTIC VALUE; ENDOTHELIUM CELL; FEMALE; HUMAN; METASTASIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 0032432921     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006175504673     Document Type: Review

References (105)

1. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4-6, 1989
2. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1:27-31, 1995
3. Risau W: Mechanisms of angiogenesis. Nature 386:671-674, 1997
4. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM: Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964-967, 1997
5. Hunt BJ, Jurd KM: Endothelial cell activation. A central pathophysiological process. Br Med J 316: 1328-1329, 1998
6. Folkman J: Clinical applications of research on angiogenesis. New Engl J Med 333:1757-1763, 1995
7. Folkman J: How is blood vessel growth regulated in normal and neoplastic tissue? - GHA Clowes Memorial Award Lecture. Cancer Res 46:467-473, 1986
8. Hanahan D, Folkman J: Patterns of emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364,1996
9. Kerbel RS: Commentaries on tumor angiogenesis: an introduction. Cancer Metastasis Rev 15:145-147,1996
10. Marx J: Cellular changes on the route to metastasis. Science 259:626-629, 1993
11. 3 during angiogenesis. J Clin Invest 98:426-433,1996
12. Gasparini G, Harris AL: p53 and angiogenesis in neoplasia. In: Klijn JGM (ed) Prognostic and Predictive Value of p53. Elsevier Science BV, London, 1997, pp 115-130
13. Rak J, Filmus J, Finkenzeller G, Grugel S, Marmé D, Kerbel RS: Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev 14:263-277,1995
14. 3 for angiogenesis. Science 264:569-571, 1994
15. v-integrins in tumor progression and metastasis. Sem Cancer Biol 7:129-138,1996
16. Polunovsky VA, Wendt CH, Ingbar DH, Peterson MS, Bitterman PB: Induction of endothelial cell apoptosis by TNFα: Modulation by inhibitors of protein synthesis. Exp Cell Res 214:548-594, 1994
17. Wojnowski L, Zimmer AM, Beck TW, Hahn H, Bernal R, Rapp UR, Zimmer A: Endothelial apoptosis in braf-deficient mice. Nature Genetics 16:293-297, 1997
18. O'Reilly MS, Holmgren L, Chen C, Folkman J: Angiostatin induces and sustains dormancy of human primary tumors. Nature Med 2:689-692,1996
19. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277-285, 1997
20. Melder RJ, Koerig GC, Wither BP, et al: During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nature Med 2:992-997, 1996
21. Ferrara N: Natural killer cells, adhesion and tumor angiogenesis. Nature Med 2:971-972, 1996
22. Gabrilovich DL, Chen HL, Girgis KR, et al: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nature Med 2:1096-1103, 1996
23. Adams DH, Yannelli JR, Newman W, et al: Adhesion of tumor-infiltrating lymphocytes to endothelium: a phenotypic and functional analysis. Br J Cancer 75:1421-1431, 1997
24. Terman BI, Dougher-Vermazen M: Biological properties of VEGF/VPF receptors. Cancer Metastasis Rev 15:159-163,1996
25. Dvorak HF, Brown LF, Detmar M, Dvorak AM: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146:1029-1039, 1995
26. Kieser A, Wiech HA, Brandner G, Marmé D, Kolch W: Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 9:963-969, 1994
27. Hyder SM, Murthy L, Stancel GM: Progestin regulation of vascular endothelial growth factor in human breast cancer cells. Cancer Res 58:392-395, 1998
28. Nicosia RF: What is the role of vascular endothelial growth factor-related molecules in the tumor angiogenesis? Am J Pathol 153:11-16, 1998
29. Salven P, Lymboussaki A, Heikkilä P, Jääskela-Saari H, Enholm B, Aase K, Von Euler G, Eriksson U, Alitalo K, Joensuu K: Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am J Pathol 153:103-108, 1998
30. Guidi AJ, Schnitt SJ, Fischer L, Tognazzi K, Harris JR, Dvorak HF, Brown LF: Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast. Cancer 80:1945-1953, 1997
31. Toi M, Insada K, Hoshina S, Suzuki H, Kondo S, Tominaga T: Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer. Clin Cancer Res 1:961-964, 1995
32. Anan K, Morisaki T, Katano M, Ikubo A, Kitsuki R, Uchiyama A, Kuroki S, Taoaka M, Torisu M: Vascular endothelial growth factor and platelet-derived growth factor are potential angiogenic and metastatic factors in human breast cancer. Surgery 119:333-339, 1996
33. Obermair A, Kucera E, Mayerhofer K, Speiser P, Seifert M, Czerwenka K, Kaider A, Leodalter S, Kaintz C, Zeillinger R: Vascular endothelial growth factor (VEGF) in human breast cancer: correlation with disease-free survival. Int J Cancer 74:455-458, 1997
34. Toi M, Gion M, Biganzoli E, Dittadi R, Boracchi P, Miceli R, Meli S, Mori K, Tominaga T, Gasparini G: Co-determination of the angiogenic factors thymidine phosphorylase and vascular endothelial growth factor in node-negative breast cancer: prognostic implications. Angiogenesis 1:71-83, 1997
35. Gasparini G, Toi M, Gion M, Verderio P, Dittadi R, Hanatani M, Matsubara I, Vinante O, Bonoldi E, Boracchi P, Gatti C, Suzuki I, Tominaga T: Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 89:139-147, 1997
36. Relf M, LeJeune S, Scott PAE, Fox S, Smith K, Leek R, Moghaddam A, Whitehouse R, Bicknell R, Harris AL: Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet-derived endothelial growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57:963-969,1997
37. Vermeulen PB, Dirix LY, Salven P, Benoy L, Ranieri G, Toi M, Gasparini G: Assessing angiogenic factor concentrations in body fluids of cancer patients and in tumor cytosols: a review. Angiogenesis, in press
38. Vermeulen PB, Salven P, Benoy L, Gasparini G, Dirix LY: Blood platelets and serum VEGF in cancer patients. Br J Cancer, in press
39. Verheul HMW, Haekman K, Luykx-de Bakker S, Eekman CA, Folman CC, Broxterman HJ, Pinedo HM: Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 3:2187-2190, 1997
40. Folkman J: What is the rote of thymidine phosphorylase in tumor angiogenesis? J Natl Cancer Inst 88:1091-1092,1996
41. Griffths L, Stratford IJ: Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumor growth and response to therapy. Br J Cancer 76:689-693, 1997
42. Piper AA, Tattersall MHN, Fox RM: The activities of thymidine metabolising enzymes during the cell cycle of human lymphocyte cell line LAZ-007 synchronised by centrifugal elutriation. Biochim Biophys Acta 633:400-409, 1980
43. Fox SB, Westwood M, Moghaddam A, Comley M, Turley H, Whitehouse RM, Bicknell R, Gatter KC, Harris AL: The angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase is up-regulated in breast cancer epithelium and endothelium. Br J Cancer 73:275-280,1996
44. Toi M, Hoshina S, Taniguchi T, Yamamoto Y, Ishitsuka H, Tominaga T: Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast cancer. Int J Cancer 64:79-82, 1995
45. Seymour L, Bezwoda WR: Positive immunostaining for platelet derived growth factor (PDGF) is an adverse prognostic factor in patients with advanced breast cancer. Breast Cancer Res Treat 32:229-233, 1994
46. Engels K, Fox SB, Whitehouse RM, Gatter KC, Harris AL: Up-regulation of thymidine phosphorylase expression is associated with a discrete pattern of angiogenesis in ductal carcinomas in situ of the breast. J Pathol 182:414-420, 1997
47. Fox SB, Engels K, Comley M, Whitehouse RM, Turley H, Gatter KC, Harris AL: Relationship of elevated tumor thymidine phosphorylase in node-positive breast carcinomas to rite effects of adjuvant CMF. Ann Oncol 8:271-275, 1997
48. Nagaoka H, Iino Y, Takei H, Morishita Y: Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in macrophages correlates with tumor angiogenesis and prognosis in invasive breast cancer. Int J Oncol 13:449-454, 1998
49. Gion M, Toi M, Dirix L, Dittadi R, Fanelli M, Vermeulen P, Gasparini G: Clinical significance of cytosolic levels in primary node-positive breast cancer of vascular endothelial growth factor and thymidine phosphorylase [Abstr 412]. Proc Amer Soc Clin Oncol, 1998, p 107a
50. Leek RD, Landers R, Fox SB, Ng F, Harris AL, Lewis CE: Association of tumor necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. Br J Cancer 77:2246-2251, 1998
51. Nagy J, Curry GW, Hillan KJ, Mallon E, Pumshotham AD, George WD: Hepatocyte growth factor/scatter factor, angiogenesis and tumor cell proliferation in primary breast cancer. Breast 5:105-109,1996
52. Laterra J, Nam M, Rosen E, Rao JS, Lamszus K, Goldberg ID, Johnston P: Scatter factor/hepatocyte growth factor gene transfer enhances glioma growth and angiogenesis in vivo. Lab Invest 76:565-577, 1997
53. Taniguchi T, Toi M, Inada K, Imazawa T, Yamamoto Y, Tominaga T: Serum concentrations of hepatocyte growth factor in breast cancer patients. Clin Cancer Res 1:1031-1034, 1995
54. Mason IJ: The ins and outs of fibroblast growth factors. Cell 78:547-552, 1994
55. Kern FG, Lippman ME: The role of angiogenic growth factors in breast cancer progression. Cancer Metastasis Rev 15:213-219, 1996
56. Zhang L, Kharbanda S, Chen D, Bullocks J, Miller DL, Ding IY, Hanfelt J, McLeskey SW, Kern FG: MCF-7 breast carcinoma cells overexpressing FGF-1 form vascularized, metastatic tumors in ovariectomized or tamoxifen-treated nude mice. Oncogene 15:2093-2108, 1997
57. Colomer R, Aparicio J, Montero S, Guzmán C, Larrodera L, Cortés-Funies H: Low levels of basic fibro-blast growth factor (bFGF) are associated with a poor prognosis in human breast carcinoma. Br J Cancer 76:1215-1220, 1997
58. Yiangou C, Gomm JJ, Coope RC, Law M, Luqmani YA, Shousha S, Coombes RC, Johnston CL: Fibroblast growth factor 2 in breast cancer: occurrence and prognostic significance. Br J Cancer 75:28-33, 1997
59. Visscher DW, De Mattia F, Ottosen S, Sarkar FH, Crissman JD: Biologic and clinical significance of basic fibroblast growth factor immunostaining in breast carcinoma. Modern Pathol 8:665-670, 1995
60. Dirix LY, Vermeulen PB, Pawinski A, Prové A, Benoy I, De Pooter C, Martin M, Van Oosterom AT: Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br J Cancer 76:238-243, 1997
61. Coope RC, Browne PJ, Yiangou C, Bansal GS, Walters J, Groome N, Shousha S, Johnston CL, Coombes RC, Gomm JJ: The location of acidic fibroblast growth factor in the breast is dependent on the activity of proteases present in breast cancer tissue. Br J Cancer 75:1621-1630, 1997
62. Scott PA, Smith K, Poulsom R, De Benedetti A, Bicknell R, Hams AL: Differential expression of vascular endothelial growth factor mRNA vs protein isoform expression in human breast cancer and relationship to eIF-4E. Br J Cancer 77:2120-2128, 1998
63. Morelli D, Lazzerini D, Cazzaniga S, Squicciarini P, Bignami P, Maier JAM, Sfondrini L, Menard S, Colnaghi MI, Bolsari A: Evaluation of the balance between angiogenic and antiangiogenic circulating factors in patients with breast and gastrointestinal cancers. Clin Cancer Res 4:1221-1225, 1998
64. Yamashita J, Ogawa M, Jamashita S, Nomura K, Kuramoto M, Saishoji T, Shin S: Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res 54:1630-1633, 1994
65. Toi M, Hoshima S, Takayanagi T, Tominaga T: Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn J Cancer Res 85:1045-1049, 1994
66. th NCI-EORTC symposium on new drugs in cancer therapy, Amsterdam. Ann Oncol 9 (suppl 2):522, 1998
67. Toi M, Taniguchi T, Yamamoto Y, Kurisaki H, Tominaga T: Clinical significance of the determination of angiogenic factors. Eur J Cancer 32A:2513-2519, 1996
68. Linderholm B, Tavelin B, Grankvist K, Henriksson R: Vascular endothelial growth factor protein-A predictor of survival in primary breast cancer [Abstr 386]. Proc Amer Soc Clin Oncol, 1998, p100a
69. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362:841-844, 1993
70. Hori A, Sasada R, Matsutani E, Naito K, Sakura Y, Fujita T, Kozai Y: Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res 51:6180-6184, 1991
71. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK: Time-dependent vascular regression and permeability changes in established human tumor xenografts reduced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA 93:14765-14770,1996
72. Gasparini G: Antiangiogenic drugs as a novel anti-cancer therapeutic strategy. Which are the more promising agents? What are the clinical developments and indications? Crit Rev Oncol Hematol 26:147-162, 1997
73. Gordon MS, Talpalz M, Margolin K, et al: Phase I trial of recombinant humanized monoclonal anti-vascular endothelial growth factor (anti-VEGF MAB) in patients with metastatic cancer [Abstr 809]. Proc Amer Soc Clin Oncol 17:210, 1998
74. Bertin N, Clezardin P, Kubiak R, Frappart L: Thrombospondin 1 and 2 messenger RNA expression in normal, benign, and neoplastic human breast tissues: correlation with prognostic factors, tumor angiogenesis, and fibroblastic desmoplasia. Cancer Res 57:396-399, 1997
75. Roth JJ, Reiver DM, Granik MS, Rothman VL, Nicosia RF, Tuszynski GP: Histopathology and clinical assessment correlate with the cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) receptor of thrombospondin-1 in breast tumors. Histol Histopathol 12:1013-1018, 1997
76. Weinstat-Saslow DL, Zabrenetzky VS, VanHoutte K, Frazier WA, Roberts DD, Steeg PS: Transfection of thrombospondin I complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res 54:6504-6511, 1994
77. Volpert O, Stellmach V, Bouck N: The modulation of thrombospondin and other naturally occurring inhibitors of angiogenesis during tumor progression. Breast Cancer Res Treat 36:119-126,1995
78. Zajchowski DA, Band V, Trask DK, Kling D, Connolly JL, Sager R: Suppression of tumor-forming ability and related traits in MCF-7 human breast cancer cell by fusion with immortal mammary epithelial cells. Proc Natl Acad Sci USA 87:2314-2318, 1990
79. Xu M, Kumar D, Strass SA, Mixson AJ: Gene therapy with p53 and fragment of thrombospondin-1 inhibits human breast cancer in vivo. Mol Genet Metab 63:103-109, 1998
80. Dameron KM, Volpert OV, Tainsky MA, Bouck N: Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265:1582-1585, 1994
81. Incardona F, Leivalle JM, Morandi V, Lambert S, Legrand Y, Foidart JM, Legrand C: Thrombospondin modulates human breast adenocarcinoma cell adhesion to human vascular endothelial cells. Cancer Res 55:166-173,1995
82. Arnoletti JP, Albo D, Granick MS, Solomon MP, Castiglioni A, Rothman VL, Tuzynski GP: Thrombospondin and transforming growth-factor beta 1 increase expression of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in human MDA-MB-231 breast cancer cells. Cancer 76:998-1005,1995
83. Griscelli F, Li H, Bennaceur-Griscelli A, Soria J, Opolon P, Sofia C, Perricaudet M, Yeh P, Lu H: Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc Natl Acad Sci 95:6367-6372, 1998
84. Zhu BT, Conney AH: Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis? Cancer Res 58:2269-2277, 1998
85. Fotsis TH, Zhang Y, Pepper MS, Adlercreutz H, Montesano R, Nawroth PP, Schwelgerer L: The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumor growth. Nature 368:237-239, 1994
86. Bischoff J: Cell adhesion and angiogenesis. J Clin Invest 99:373-376, 1997
87. Fox SB, Leek RD, Weekes MP, Whitehouse RM, Gatter KC, Harris AL: Quantitation and prognostic value of breast cancer angiogenesis: Comparison of microvessel density, Chalkley count and computer image analysis. J Pathol 177:275-283, 1995
88. Charpin C, Bergeret D, Garcia S, Andrac L, Martini F, Horschowski N, Choux R, Lavaut MN: ELAM selectin expression in breast carcinomas detected by automated and quantitative immunohistochemical assays. Int J Oncol 12:1041-1048, 1998
89. Ruoslahti E, Engvall E: Perspectives Series: Cell adhesion in vascular biology. J Clin Invest 99:1149-1152, 1997
90. 6 integrin in human breast carcinoma is correlated with reduced survival. Cancer Res 55:901-906,1995
91. Tagliabue E, Ghirelli C, Squicciarini P, Aiello P, Colnaghi MI, Menard S: Prognostic value of alpha 6 beta 4 integrin expression in breast carcinoma is affected by laminin production from tumor cells. Clin Cancer Res 4:407-410, 1998
92. 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 96:1815-1822, 1995
93. 3: a prognostic indicator in breast cancer patients. Clin Cancer Res, in press
94. 3 [Abstr 832]. Proc Amer Soc Clin Oncol 17:215, 1998
95. 3-targeted magnetic resonance imaging. Nature Med 4:623-626, 1998
96. Natali PG, Nicotra MR, Bigotti A, Botti C, Castellani P, Risso AM, Zardi L: Comparative analysis of the expression of the extracellular matrix protein tenascin in normal human fetal, adult and tumor tissues. Int J Cancer 47:811-816, 1991
97. Ishihara A, Yoshida T, Tamaki H, Sakakura T: Tenascin expression in cancer cells and stroma of human breast cancer and its prognostic significance. Clin Cancer Res 1:1035-1041,1995
98. Contrino J, Hair G, Kreutzer DL, Rickles FR: In situ detection of tissue factor in vascular endothelial cells: Correlation with the malignant phenotype of human breast disease. Nature Med 2:209-215,1996
99. Gasparini G, Barbareschi M, Boracchi P, Bevilacqua P, Verderio P, Dalla Palma P, Menard S: 67-kDa laminin-receptor expression adds prognostic information to intra-tumoral microvessel density in node-negative breast cancer. Int J Cancer 60:604-610, 1995
100. Folkman J: The influence of angiogenesis research on management of patients with breast cancer. Breast Cancer Res Treat 36:109-118,1995
101. Gasparini G: Angiogenesis in breast cancer: Role in biology, tumor progression, and prognosis. In: Bowcock A (ed) Breast Cancer. Humana Press, in press, 1998
102. Gasparini G: Is determination of angiogenic activity in human tumours clinically useful? Eur J Cancer 34:615-618, 1998
103. Jain RK, Schlenger K, Hockel M, Yuan F: Quantitative angiogenesis assays: Progress and problems. Nature Med 3:1203-1208, 1997
104. Gasparini G, Presta M: Clinical studies with angiogenesis inhibitors: biological rationale and challenges for their evaluation. Ann Oncol 7:441-444, 1996
105. Gasparini G: The rationale and future potential of angiogenesis inhibitors in neoplasia. Drugs, in press